Abstract

ObjectivesThe aim of this 12-week Phase IIb study was to assess the efficacy and safety of olokizumab (OKZ), a humanised anti-IL6 monoclonal antibody, in patients with rheumatoid arthritis (RA) with...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study
M.E. Luggen ... S. Grishin
Modern Rheumatology Journal | VOL. 17
M.E. Luggen, et. al.M.E. Luggen ... S. Grishin
22 Apr 2023
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study
Roy M Fleischmann ... Eugen Feist
Annals of the Rheumatic Diseases | VOL. 81
Roy M Fleischmann, et. al.Roy M Fleischmann ... Eugen Feist
15 Sep 2022
Rheumatology meeting: Efficacy, safety of biologics central focus
Maria G. Tanzi
Pharmacy Today | VOL. 19
Maria G. TanziMaria G. Tanzi
01 Apr 2013
Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies.
Patrick Durez ... Elena Korneva
European journal of rheumatology | VOL. 8
Patrick Durez, et. al.Patrick Durez ... Elena Korneva
27 Sep 2021
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Retraction: PKCδ null mutations in a mouse model of osteoarthritis alter osteoarthritic pain independently of joint pathology by augmenting NGF/TrkA-induced axonal outgrowth
-
Annals of the Rheumatic Diseases | VOL. -
--
22 Apr 2024
Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease.
Andrea R Daamen ... Peter E Lipsky
Annals of the rheumatic diseases | VOL. -
Andrea R Daamen, et. al.Andrea R Daamen ... Peter E Lipsky
18 Apr 2024
Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events
Dionysis Nikolopoulos ... Dimitrios T Boumpas
Annals of the Rheumatic Diseases | VOL. -
Dionysis Nikolopoulos, et. al.Dionysis Nikolopoulos ... Dimitrios T Boumpas
12 Apr 2024
Risk of cardiovascular disease with high-dose versus low-dose use of non-steroidal anti-inflammatory drugs in ankylosing spondylitis
Ji-Won Kim ... Jung-Yoon Choe
Annals of the Rheumatic Diseases | VOL. -
Ji-Won Kim, et. al.Ji-Won Kim ... Jung-Yoon Choe
09 Apr 2024
View more papers